pharmaceutical · input
Seasonal quadrivalent influenza vaccine (QIV) protects against 4 influenza strains chosen annually by WHO strain surveillance. Cell-based production (using MDCK or Vero cells instead of chicken eggs) eliminates egg adaptation mutations that reduce vaccine effectiveness. Global flu vaccine market: ~500 million doses/year; 3 major producers (CSL Seqirus ~30%, Sanofi Pasteur ~35%, GSK ~20%). Annual strain selection in February (North) and September (South) creates a 6-month production window. Cell-based manufacturing enables ~6-8 week faster response than egg-based in a pandemic. US government (CDC) distributes ~170 million doses annually for seasonal flu prevention.
1
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on seasonal influenza vaccine (cell-based quadrivalent) somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| USUnited States | 80% |
Who makes it
4 companies produce seasonal influenza vaccine (cell-based quadrivalent).
World's largest cell-based influenza vaccine manufacturer; Holly Springs, NC facility produces 150 million flu doses/year and is US government-designated pandemic-ready. Also sole producer of MF59 adjuvant used in pandemic flu and aging-population flu vaccines.
UK pharmaceutical company; sole manufacturer and formulator of AS01B adjuvant system (QS-21 + MPL in liposomes); used in Shingrix (herpes zoster vaccine, $4B+ annual revenue) and RTS,S/Mosquirix (malaria vaccine); retaining AS01E adjuvant supply even as malaria vaccine manufacturing transfers to Bharat Biotech
mRNA vaccine maker; $176M BARDA grant to develop mRNA pandemic influenza (H5N1) vaccine — egg- and cell-free platform.
Largest seasonal flu vaccine maker (~35%); egg-based Fluzone and recombinant Flublok; FDA-approved H5N1 pandemic vaccine.
™Your Policy Risk Impact Agent